PaxMedica, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PaxMedica, Inc. - overview
Established
2018
Location
-, NY, US
Primary Industry
Biotechnology
About
Founded in 2018 by Michael Derbyand and based in New York, US, PaxMedica, Inc. is a clinical-stage biopharmaceutical company specialising in neurodevelopmental disorders. As of 2022, Howard Weisman is the CEO of the company. In November 2022, Lincoln Park Capital agreed to acquire PaxMedica, Inc.
for USD 20 million. The company is traded on the NASDAQ under the ticker symbol PXMD. The company is developing its lead programs, such as PAX-101 (intravenous suramin) and PAX-102 (intranasal suramin). The firm’s lead programmes are focused on the treatment of autism spectrum disorder (ASD) and fragile X-associated tremor or ataxia (FXTAS).
PaxMedica collaborates with companies, academia, patient advocacy groups, and other industry stakeholders.
Current Investors
Lincoln Park Capital, The Lind Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.paxmedica.com
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
PaxMedica, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | PaxMedica, Inc. | - | ||||||||
| PIPE | Completed | PaxMedica, Inc. | - | ||||||||
| LP Direct | Completed | PaxMedica, Inc. | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.